Merck & Co., Inc. (MRK)’s Investigational Grass Sublingual Allergy Immunotherapy Tablet Significantly Reduced Allergy Symptoms and Need for Symptom-Relief Medication in Adults and Children in Pivotal Phase 3 Study
11/10/2013 12:35:34 AM
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced data for its investigational Timothy grass sublingual allergy immunotherapy tablet (MK-7243) from a study involving 1,501 North American adult and pediatric patients. Results showed that MK-7243 demonstrated significant improvement in Total Combined Score (TCS) averaged over the entire grass pollen season (the primary endpoint), which was the sum of the rhinoconjunctivitis daily symptom score (DSS) and the daily medication score (DMS), compared to placebo. Researchers will present findings at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting, Nov. 7-11, in Baltimore.
Help employers find you! Check out all the jobs and post your resume.
comments powered by